Bausch Health Reports Q3 Consolidated Revenues of $2.68 Billion

Bausch Health Companies reported Q3 consolidated revenues of $2.68 billion. The company's segments include Salix (US GI products), International (branded pharmaceuticals outside the US), Solta Medical (aesthetic medical devices), Diversified (neurology and other therapeutic classes in the US), and Bausch + Lomb (global vision care, surgical, and pharmaceutical products).